Ultragenyx Pharmaceutical (GB:0LIF)

Ultragenyx Pharmaceutical (0LIF) Share Price & Analysis


0LIF Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$33.90 - $65.69
Previous Close$52.07
Average Volume (3M)242.00
Market Cap
Enterprise Value$3.02B
Total Cash (Recent Filing)$629.35M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)N/A
Aug 03, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
Shares Outstanding70,814,462
10 Day Avg. Volume49
30 Day Avg. Volume242
Standard Deviation0.20
Financial Highlights & Ratios
Price to Book (P/B)-453.26
Price to Sales (P/S)100.53
Price to Cash Flow (P/CF)-5.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.88
Enterprise Value/Gross Profit9.44
Enterprise Value/Ebitda-4.23
Price Target Upside74.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12




What was Ultragenyx Pharmaceutical’s price range in the past 12 months?
Ultragenyx Pharmaceutical lowest share price was $33.90 and its highest was $65.69 in the past 12 months.
    What is Ultragenyx Pharmaceutical’s market cap?
    Currently, no data Available
    When is Ultragenyx Pharmaceutical’s upcoming earnings report date?
    Ultragenyx Pharmaceutical’s upcoming earnings report date is Aug 03, 2023 which is in 54 days.
      How were Ultragenyx Pharmaceutical’s earnings last quarter?
      Ultragenyx Pharmaceutical released its earnings results on May 04, 2023. The company reported -$2.33 earnings per share for the quarter, missing the consensus estimate of -$1.992 by -$0.338.
        Is Ultragenyx Pharmaceutical overvalued?
        According to Wall Street analysts Ultragenyx Pharmaceutical’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Ultragenyx Pharmaceutical pay dividends?
          Ultragenyx Pharmaceutical does not currently pay dividends.
          What is Ultragenyx Pharmaceutical’s EPS estimate?
          Ultragenyx Pharmaceutical’s EPS estimate is -$2.07.
            How many shares outstanding does Ultragenyx Pharmaceutical have?
            Currently, no data Available
            What happened to Ultragenyx Pharmaceutical’s price movement after its last earnings report?
            Ultragenyx Pharmaceutical reported an EPS of -$2.33 in its last earnings report, missing expectations of -$1.992. Following the earnings report the stock price went up 16.633%.
              Which hedge fund is a major shareholder of Ultragenyx Pharmaceutical?
              Among the largest hedge funds holding Ultragenyx Pharmaceutical’s share is Baker Bros Advisors LP. It holds Ultragenyx Pharmaceutical’s shares valued at 19M.


                Ultragenyx Pharmaceutical Stock Smart Score

                The Ultragenyx Pharmaceutical Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                Learn more about TipRanks Smart Score

                Company Description

                Ultragenyx Pharmaceutical

                Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. Mepsevii is an intravenous, which is used for the treatment of Mucopolysaccharidosis VII. Crysvita is an antibody administered via subcutaneous injection used for the treatment of XLH. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.


                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                Ultragenyx Pharmaceutical
                Sarepta Therapeutics
                Bluebird Bio
                Agios Pharma
                BioMarin Pharmaceutical

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis